Germline and somatic mutations affecting HRR genes are relatively commonplace, affecting approximately one-third of ovarian carcinoma patients, with BRCA1 and BRCA2 mutations being the most prevalent [15]. This evidence concerns the gene BRCA2 and ovarian carcinoma.